{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:53:50Z","timestamp":1790873630768,"version":"4.1.0"},"reference-count":59,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life\u2010threatening psychiatric events in some individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted disproportionality analyses using case reports involving adverse events related to dependence, withdrawal, suicidality and psychosis, submitted to Australia's Therapeutic Goods Administration between 2005 and 2024. Reporting odds ratios (RORs) were calculated to determine whether these adverse events were disproportionately reported for pregabalin compared to all other drugs in the database and to an active comparator group of other neuropathic pain drugs (gabapentin, duloxetine and amitriptyline).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to all other drugs in the database, pregabalin showed strong signals of disproportionate reporting for drug abuse and dependence (ROR\u2009=\u200913.53, 95% confidence interval [CI]: 12.12, 15.10), drug withdrawal (ROR\u2009=\u20096.76, 95% CI: 4.99, 9.15), suicide and self\u2010injury (ROR\u2009=\u200912.40, 95% CI: 10.71, 14.36), and psychosis and psychotic disorders (ROR\u2009=\u20095.81, 95% CI: 4.99, 6.76). When compared to other neuropathic pain drugs, the signal of disproportionate reporting remained for drug abuse and dependence (ROR\u2009=\u20091.38, 95% CI: 1.17, 1.62) and psychosis and psychotic disorders (ROR\u2009=\u20091.26, 95% CI: 1.002, 1.57), albeit with less pronounced effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adverse events related to drug dependence and psychosis are reported to the Australian pharmacovigilance database at a higher rate for pregabalin compared to other drugs, including other neuropathic pain drugs, signalling a potential concern that warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70279","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:38:06Z","timestamp":1758872286000},"page":"545-555","source":"Crossref","is-referenced-by-count":5,"title":["Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7112-042X","authenticated-orcid":false,"given":"Amy G.","family":"McNeilage","sequence":"first","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"},{"name":"Monash Addiction Research Centre, Eastern Health Clinical School Monash University  Frankston Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8674-450X","authenticated-orcid":false,"given":"Ali","family":"Gholamrezaei","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-3025","authenticated-orcid":false,"given":"Bridin","family":"Murnion","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"},{"name":"School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-1055","authenticated-orcid":false,"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School Monash University  Frankston Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-4295","authenticated-orcid":false,"given":"Claire E.","family":"Ashton\u2010James","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20x101120"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010023\u201040637\u20108"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1071\/ah20060"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010025\u201001915\u20101"},{"key":"e_1_2_12_6_1","volume-title":"PBS expenditure and prescriptions twelve months to 30 June 2014","author":"Pharmaceutical Benefits Scheme","year":"2014"},{"key":"e_1_2_12_7_1","volume-title":"PBS expenditure and prescriptions twelve months to 30 June 2018","author":"Pharmaceutical Benefits Scheme","year":"2018"},{"key":"e_1_2_12_8_1","volume-title":"PBS expenditure and prescriptions report 1 July 2023 to 30 June 2024","author":"Pharmaceutical Benefits Scheme","year":"2024"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jppr.1693"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd007076.pub3"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2010.02966.x"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2014.01.005"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14412"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.12036"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001432\u20107"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104605"},{"issue":"10","key":"e_1_2_12_17_1","first-page":"705","article-title":"Changes in mood, depression and suicidal ideation after commencing pregabalin for neuropathic pain","volume":"43","author":"Hall T","year":"2014","journal-title":"Aust Fam Physician"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12195"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/24750573.2018.1452523"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360\u2010020\u20100395\u20106"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010024\u201001423\u20107"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15802"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2011.04037.x"},{"key":"e_1_2_12_25_1","unstructured":"Department of Health and Aged Care.Report a problem or side effect: Commonwealth of Australia. Available from:https:\/\/www.tga.gov.au\/safety\/reporting-problems"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256752"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010024\u201001433\u20105"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526\u20104637.2004.04019.x"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532\u20102149.2013.00334.x"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15178"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474\u20104422(14)70251\u20100"},{"key":"e_1_2_12_32_1","first-page":"1","article-title":"Neuropathic pain: diagnosis and treatment today","author":"Siddall P","year":"2018","journal-title":"Medicinewise News"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107709"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010016\u20100421\u2010z"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.06.018"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010016\u20100359\u2010y"},{"key":"e_1_2_12_37_1","volume-title":"Pharmacovigilance responsibilities of medicine sponsors: Australian recommendations and requirements","author":"Therapeutic Goods Administration","year":"2012"},{"key":"e_1_2_12_38_1","unstructured":"JASP Team.JASP [software]. Version 0.19.3. 2025."},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16178"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16182"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2021.1965159"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.7326\/m18\u20101136"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.640264"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2448833"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.08.430"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13892"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l2147"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536200\u2010000000000\u201000000"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1833"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619836032"},{"key":"e_1_2_12_51_1","unstructured":"Lyrica \u2010 Package Insert.Food and Drug Administration. ; Available from:https:\/\/www.fda.gov\/drugsatfda"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380\u2010024\u201002782\u20104"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010022\u201001246\u20104"},{"key":"e_1_2_12_54_1","unstructured":"Australian Product Information.APO\u2010DULOXETINE (duloxetine hydrochloride).Therapetic Goods Administration;2024. Available from:https:\/\/www.tga.gov.au\/resources\/artg\/427037"},{"key":"e_1_2_12_55_1","unstructured":"Australian Product Information.APX\u2010AMITRIPTYLINE (amitriptyline hydrochloride).Therapeutic Goods Administration;2021. Available from:https:\/\/www.tga.gov.au\/resources\/artg\/333510"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200629050\u201000003"},{"key":"e_1_2_12_57_1","unstructured":"Therapeutic Goods Administration.2021.Pregabalin and gabapentin: Safety advisory \u2010 enhanced warnings relating to abuse and dependence. Available from:https:\/\/www.tga.gov.au\/news\/safety-alerts\/pregabalin-and-gabapentin"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.01.015"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200730070\u201000011"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.2307\/2686095"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70279","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70279","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:55:24Z","timestamp":1770908124000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/bcp.70279"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70279","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}